R. A. de Boer

Phenotypic and Genetic Factors Associated with Absence of Cardiomyopathy Symptoms in PLN:c.40_42delAGA Carriers

L. Franke, R. D. de Boer, Patrick Deelen, 2023, Journal of cardiovascular translational research.

The Time Has Come to Explore Plasma Biomarkers in Genetic Cardiomyopathies

R. D. de Boer, M. P. van den Berg, H. Silljé, 2021, International journal of molecular sciences.

Optimal echocardiographic assessment of myocardial dysfunction for arrhythmic risk stratification in phospholamban mutation carriers

A. Wilde, R. D. de Boer, M. P. van den Berg, 2021, European heart journal. Cardiovascular Imaging.

Early Mechanical Alterations in Phospholamban Mutation Carriers: Identifying Subclinical Disease Before Onset of Symptoms.

A. Wilde, R. D. de Boer, M. P. van den Berg, 2020, JACC. Cardiovascular imaging.

Exploring the Correlation Between Fibrosis Biomarkers and Clinical Disease Severity in PLN p.Arg14del Patients

R. D. de Boer, M. Vos, T. V. van Veen, 2022, Frontiers in Cardiovascular Medicine.

BIO FOr CARE: biomarkers of hypertrophic cardiomyopathy development and progression in carriers of Dutch founder truncating MYBPC3 variants—design and status

A. Wilde, R. D. de Boer, F. Asselbergs, 2021, Netherlands Heart Journal.

Sex-specific aspects of phospholamban cardiomyopathy: the importance and prognostic value of low-voltage ECGs.

R. D. de Boer, M. P. van den Berg, A. Wilde, 2021, Heart rhythm.

Rationale and design of the PHOspholamban RElated CArdiomyopathy intervention STudy (i-PHORECAST)

I. V. Van Gelder, H. Tan, R. D. de Boer, 2021, Netherlands Heart Journal.

Circulating Acylcarnitines Associated with Hypertrophic Cardiomyopathy Severity: an Exploratory Cross-Sectional Study in MYBPC3 Founder Variant Carriers

R. D. de Boer, A. Baas, J. Jans, 2023, Journal of cardiovascular translational research.